

UC Irvine

UC Irvine Previously Published Works

Title

Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate A β in Down Syndrome and Sporadic Alzheimer's Disease

Permalink

<https://escholarship.org/uc/item/375279k1>

Authors

Pivtoraiko, Violetta N
Racic, Tamara
Abrahamson, Eric E
et al.

Publication Date

2021

DOI

10.3389/fnagi.2021.728739

Peer reviewed



Postmortem Neocortical ³H-PiB Binding and Levels of Unmodified and Pyroglutamate A β in Down Syndrome and Sporadic Alzheimer's Disease

Violetta N. Pivtoraiko^{1,2†}, Tamara Racic^{2†}, Eric E. Abrahamson^{1,2}, Victor L. Villemagne³, Benjamin L. Handen³, Ira T. Lott⁴, Elizabeth Head⁵ and Milos D. Ikonomic^{1,2,3*}

¹Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States, ²Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, ³Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, ⁴Department of Neurology, UC Irvine School of Medicine, Orange, CA, United States, ⁵Department of Pathology and Laboratory Medicine, UC Irvine School of Medicine, Orange, CA, United States

OPEN ACCESS

Edited by:

Stephen D. Ginsberg,
Nathan Kline Institute for Psychiatric
Research, United States

Reviewed by:

David Morgan,
Michigan State University,
United States
Seth Love,
University of Bristol, United Kingdom

*Correspondence:

Milos D. Ikonomic
ikonomicmd@upmc.edu

[†]These authors have contributed
equally to this work and share first
authorship

Received: 22 June 2021

Accepted: 20 July 2021

Published: 13 August 2021

Citation:

Pivtoraiko VN, Racic T,
Abrahamson EE, Villemagne VL,
Handen BL, Lott IT, Head E and
Ikonomic MD (2021) Postmortem
Neocortical ³H-PiB Binding and
Levels of Unmodified and
Pyroglutamate A β in Down
Syndrome and Sporadic
Alzheimer's Disease.
Front. Aging Neurosci. 13:728739.
doi: 10.3389/fnagi.2021.728739

Individuals with Down syndrome (DS) have a genetic predisposition for amyloid- β (A β) overproduction and earlier onset of A β deposits compared to patients with sporadic late-onset Alzheimer's disease (AD). Positron emission tomography (PET) with Pittsburgh Compound-B (PiB) detects fibrillar A β pathology in living people with DS and AD, but its relationship with heterogeneous A β forms aggregated within amyloid deposits is not well understood. We performed quantitative *in vitro* ³H-PiB binding assays and enzyme-linked immunosorbent assays of fibrillar (insoluble) unmodified A β 40 and A β 42 forms and N-terminus truncated and pyroglutamate-modified A β NpE3-40 and A β NpE3-42 forms in postmortem frontal cortex and precuneus samples from 18 DS cases aged 43–63 years and 17 late-onset AD cases aged 62–99 years. Both diagnostic groups had frequent neocortical neuritic plaques, while the DS group had more severe vascular amyloid pathology (cerebral amyloid angiopathy, CAA). Compared to the AD group, the DS group had higher levels of A β 40 and A β NpE3-40, while the two groups did not differ by A β 42 and A β NpE3-42 levels. This resulted in lower ratios of A β 42/A β 40 and A β NpE3-42/A β NpE3-40 in the DS group compared to the AD group. Correlations of A β 42/A β 40 and A β NpE3-42/A β NpE3-40 ratios with CAA severity were strong in DS cases and weak in AD cases. Pyroglutamate-modified A β levels were lower than unmodified A β levels in both diagnostic groups, but within group proportions of both pyroglutamate-modified A β forms relative to both unmodified A β forms were lower in the DS group but not in the AD group. The two diagnostic groups did not differ by ³H-PiB binding levels. These results demonstrate that compared to late-onset AD cases, adult DS individuals with similar severity of neocortical neuritic plaques and greater CAA pathology have a preponderance of both pyroglutamate-modified A β NpE3-40 and unmodified A β 40 forms. Despite the distinct molecular profile of A β forms and greater vascular amyloidosis in DS cases, cortical ³H-PiB binding does not distinguish between

diagnostic groups that are at an advanced level of amyloid plaque pathology. This underscores the need for the development of CAA-selective PET radiopharmaceuticals to detect and track the progression of cerebral vascular amyloid deposits in relation to A β plaques in individuals with DS.

Keywords: Alzheimer's disease, amyloid, cerebral amyloid angiopathy, default mode network, Down syndrome, Pittsburgh Compound-B, pyroglutamate

INTRODUCTION

Individuals with Down syndrome (DS) have an overabundance of amyloid- β (A β) peptide production due to trisomy of chromosome 21, which harbors the A β -precursor protein (APP) gene (Oyama et al., 1994), and they typically develop Alzheimer's disease (AD) pathology by the fifth decade of life (Davidson et al., 2018). The primary histopathological features of AD that are present in the DS brain include amyloid plaque deposits of fibrillar A β peptides and neurofibrillary tangles of over-phosphorylated tau protein (Wisniewski et al., 1985; Mann, 1988; Dickson, 2005; Head et al., 2016; Davidson et al., 2018; Perez et al., 2019). As in AD, fibrillar A β also accumulates in the brain vasculature (cerebral amyloid angiopathy, CAA) in the DS brain, at levels exceeding those seen in normal aging (Vinters, 1987; Carmona-Iragui et al., 2017; Head et al., 2017; Davidson et al., 2018).

Recent improvements in medical care have contributed to the increased longevity of individuals with DS, and advancements in diagnostic biomarkers have facilitated studies of key questions regarding the interconnected clinical and neuropathological features that develop with age in DS (Neale et al., 2018; Handen et al., 2020; Head and Ances, 2020; Petersen et al., 2020, 2021; Rafii et al., 2020; Hendrix et al., 2021). Positron emission tomography (PET) studies using Pittsburgh Compound-B (¹¹C-PiB) and related amyloid-binding radiopharmaceuticals provide insight into regional distributions and temporal changes in A β pathology in living people with AD (Klunk et al., 2004; Rowe et al., 2007; Cohen et al., 2012; Mathis et al., 2017; Villemagne et al., 2021) and this technology is being applied increasingly to studies of individuals with DS (Landt et al., 2011; Handen et al., 2012; Hartley et al., 2014, 2017, 2020; Annus et al., 2016, 2017; Lao et al., 2016, 2017, 2018; Cole et al., 2017; Cohen et al., 2018; Neale et al., 2018; Mak et al., 2019a,b; Mihaila et al., 2019; Tudorascu et al., 2019, 2020; Wilson et al., 2019; Cody et al., 2020; Zammit et al., 2020, 2021). PET imaging of brain A β pathology and brain metabolism as well as functional connectivity (fMRI) studies have shown that certain brain regions are more vulnerable than others to pathological changes in AD. Cortical association areas contributing to the core regions of the default mode network (DMN), including the frontal cortex, the precuneus, and the posterior cingulate cortex, show functional impairment and amyloid deposition in early AD stages (Buckner et al., 2005; Jones et al., 2011; Palmqvist et al., 2017), and these brain regions are also affected in adults with DS (Tudorascu et al., 2019; Wilson et al., 2019) suggesting that amyloid pathology affects similar cortical circuits in DS and AD. A recent longitudinal ¹¹C-PiB PET study reported

slower progression of the frontal cortex and precuneus amyloid pathology in nondemented young adults with DS (mean age 37 years) when compared to nondemented elderly (mean age 73 years; Tudorascu et al., 2019). Thus, there is a need for determining if amyloid PET ligand retention is influenced by regional differences in structural and biochemical characteristics of A β pathology in DS compared to aging and AD.

Autopsy studies demonstrated that cyano-PiB, a highly fluorescent derivative of PiB which detects A β plaques in histological sections from AD brains (Ikonomic et al., 2008, 2020), also labels A β plaques in postmortem DS brain tissue (LeVine et al., 2017; Abrahamson et al., 2019; Perez et al., 2019). In addition, analyses of *in vitro* binding of ³H-PiB to postmortem frontal cortex homogenates showed that in DS individuals higher binding levels were associated with more advanced age (LeVine et al., 2017) and that DS individuals between the ages of 43–63 years had significantly higher binding levels compared to cognitively normal elderly between the ages of 78–92 years and cases with mild-moderate AD between the ages of 77–101 years (Abrahamson et al., 2019). However, the contribution of molecularly heterogeneous A β forms (Saido et al., 1996; Roher et al., 2017), and their conformational changes when fibrillized (Schlenzig et al., 2009; Chen et al., 2017; Creekmore et al., 2021), on PiB binding is not well understood. A β peptides with the C-terminus ending at amino acid 42 predominate in A β plaques (Dickson, 1997), and are believed to be the initially deposited and a principal A β form in A β plaques in both AD and DS (Jarrett et al., 1993; Iwatsubo et al., 1994, 1995; Saido et al., 1995; Mann and Iwatsubo, 1996; Michno et al., 2019; Golde et al., 2000). In contrast, A β peptides with the C-terminus ending at the amino acid 40 are more soluble and are reported to be more prevalent in vascular A β deposits (CAA) than in parenchymal A β plaques (Jarrett et al., 1993; Miller et al., 1993; Gravina et al., 1995; Iwatsubo et al., 1995; Akiyama et al., 1997; Harigaya et al., 2000; Guntert et al., 2006; Mann et al., 2018; Gkanatsiou et al., 2019). In addition, modified A β forms with N-terminus truncations are a significant proportion of total plaque-bound A β in AD and aged DS brains (Masters et al., 1985). N-terminus truncated A β can be modified further by the enzyme glutaminyl cyclase into forms with pyroglutamate at the 3rd amino acid (A β NpE3) or the 11th amino acid (A β NpE11; Cynis et al., 2008; Schilling et al., 2008; Morawski et al., 2104). Pyroglutamate-modified A β forms are believed to play a role in seeding or maturation of A β plaques; they are more resistant to proteolytic cleavage by peptidases, which may impede their clearance, and *in vitro* they accelerate fibril formation of unmodified forms (Saido et al., 1995; He and Barrow, 1999; Schilling et al., 2006; Gunn et al.,

2010; Jawhar et al., 2011; Sullivan et al., 2011; Dammers et al., 2017; Michno et al., 2019). Both A β NpE3 and A β NpE11 forms contribute to A β plaques, however, A β NpE11 is restricted mainly to the innermost amyloid core (Sullivan et al., 2011) where it may be less accessible to peptidases as well as PET radioligands. The clinical significance of pyroglutamate A β is not known. Recent studies reported that high levels of insoluble A β 42 forms, including A β NpE3-42, correlated with cognitive impairment across clinical stages of AD (Pivtoraiko et al., 2015; Abrahamson et al., 2016). Passive immunization with a pyroglutamate-3 A β IgG1 monoclonal antibody reduced amyloid plaque burden and improved behavior in APP^{swE}/PS1 Δ E9 mice (Frost et al., 2015). In a Phase 2 clinical trial of early AD, treatment with donanemab, a humanized IgG1 monoclonal antibody developed from the mouse monoclonal antibody mE8-IgG2a (Demattos et al., 2012) and specific for A β NpE3-42, reduced A β plaque burden and slowed cognitive decline (Mintun et al., 2021). Thus, A β NpE3-42 may be an important substrate for amyloid PET ligand retention, a biomarker for brain amyloidosis, and a therapeutic target.

In adults with DS, pyroglutamate-modified A β immunoreactivity was demonstrated in cortical A β plaques at the ages 30–40 years (but not younger), with greater abundance at ages 50–70 years (Lemere et al., 1996; Frost et al., 2013). Studies have also compared N-terminally truncated, pyroglutamate-modified A β forms to other forms of A β in DS brains using biochemical methods (Saido et al., 1995; Russo et al., 1997; Hosoda et al., 1998; Gkanatsiou et al., 2021) but none in relation to binding of PiB or related amyloid PET radioligands. In the current study, we quantified fibrillar forms of unmodified A β (A β 42 and A β 40) as well as pyroglutamate-modified A β (A β NpE3-42 and A β NpE3-40) and *in vitro* binding levels of ³H-PiB (as a proxy for PiB PET imaging) in postmortem homogenates of the frontal cortex and precuneus gray matter from a group of older adults with DS (age range: 43–63 years) compared to a group of sporadic AD cases (age range: 62–99 years) with a comparable degree of AD neuropathologic change.

MATERIALS AND METHODS

Subjects

Frozen postmortem brain tissue specimens from the frontal cortex and the precuneus were obtained from 18 DS cases, provided by the University of California, Irvine Alzheimer's Disease Research Center (UCI-ADRC) and Institute for Memory Impairments and Neurological Disorders, and from 17 sporadic AD cases in the University of Pittsburgh Alzheimer's Disease Research Center (ADRC) brain bank. Clinical diagnosis of AD dementia utilized standard criteria (McKhann et al., 1984). Brain autopsy consent was obtained under a protocol approved by the Institutional Review Boards and the use of autopsy tissue for research was approved by the Committee for Oversight of Research and Clinical Training Involving Decedents (CORID) at the University of Pittsburgh and the University of California, Irvine. DS and AD brains were assessed for neocortical neuritic plaques and neurofibrillary pathology according to the

National Institute on Aging-Alzheimer's Association guidelines (Montine et al., 2012), using the Consortium to Establish a Registry for Alzheimer's disease (CERAD) neuritic plaque scoring protocol (Mirra et al., 1991) and Braak staging for neurofibrillary pathology (Braak and Braak, 1991; Braak et al., 2006). The severity of CAA was evaluated separately in the frontal cortex and in the precuneus in both diagnostic groups, using A β immunohistochemistry with mouse monoclonal IgG clone NAB228 (37-4200, Thermo-Fisher, Waltham, MA) on 4% paraformaldehyde fixed tissue sections, on a four-point rating scale (0, none; 1, mild; 2, moderate; 3, severe) by two independent evaluators (EA and MI) adapted from published studies (Olichney et al., 1995; Arvanitakis et al., 2011). Demographic and neuropathological information of cases are detailed in **Table 1**. Frozen frontal cortex was not available for one AD case (AD-9). Frozen precuneus samples were not available for two DS cases (DS-10 and DS-11) and two AD cases (AD-8 and AD-10).

Tissue Preparation

Frozen gray matter samples were homogenized in 0.01 M sodium phosphate-buffered saline (PBS, pH 7.4) to a concentration of 300 mg wet brain tissue/mL. This homogenate is referred to as a “whole (unfractionated) tissue homogenate” and was used for the ³H-PiB binding assay. A protease inhibitor cocktail (AEBSF: 104 mM, aprotinin at 80 μ M, bestatin at 4 mM, E-64 at 1.4 mM, leupeptin at 2 mM and pepstatin A at 1.5 mM; P8340, Sigma, St. Louis, MS; used at a 1:100 dilution) was added, and samples were then centrifuged at 100,000 \times g for 1 h at 4°C. The pellet was sonicated in 70% formic acid to solubilize A β fibrils. Samples were then centrifuged at 113,000 \times g for 1 h at 4°C. The supernatant containing the extracted, solubilized fibrillar A β fraction (hereafter referred to as “insoluble A β ” and assayed by the ELISA) was then removed and neutralized to pH 7.4, divided into aliquots, and frozen at –80°C until testing was performed.

Quantification of A β Peptide Levels

Solid-phase sandwich ELISA kits were used to measure A β NpE3-42 and A β NpE3-40 peptide levels (27716 and 27418, Immunobiological Laboratories, Minneapolis, MN). The A β NpE3-42 assay utilized a plate precoated with a capture antibody against the A β carboxy-terminal amino acid 42 (anti-human A β 38–42 rabbit polyclonal IgG). The A β NpE3-40 assay utilized a plate precoated with a capture antibody against the A β carboxy-terminal amino acid 40 (anti-human A β 35–40 mouse monoclonal IgG). A detection antibody for human A β NpE3 [anti-human A β N3pE (clone 8E1) mouse monoclonal IgG] was used in both assay kits. Solid phase sandwich ELISA kits were used to measure unmodified A β 42 and A β 40 peptide levels (KHB3441 and KHB3481, Thermo) on a plate precoated with a capture antibody directed against the unmodified amino terminus of A β , and detection antibodies specific for A β 42 or A β 40, respectively. Procedures were followed as outlined in the manufacturer's instructions. Optical density values were read at 450 nm with a plate reader (SpectraMax i3x, Molecular Devices, San Jose, CA, USA) using SoftMax Pro software, Version 6.5.1 (Molecular Devices). Results were determined from standard curves that used synthetic human A β NpE3-40, A β NpE3-42,

TABLE 1 | Demographic and neuropathological characteristics of Down syndrome and Alzheimer's disease cases.

Case code	Age (years)	Sex (M/F)	Neocortical neuritic plaques	Braak stage	CAA severity (frontal cortex)	CAA severity (precuneus cortex)
Down syndrome						
DS-1	49	M	Frequent	VI	None	None
DS-2	43	M	Frequent	VI	None	None
DS-3	57	F	Frequent	VI	None	Severe
DS-4	62	F	Frequent	VI	Mild	None
DS-5	45	F	Frequent	VI	Mild	Mild
DS-6	50	M	Frequent	VI	Mild	Mild
DS-7	57	F	Frequent	VI	Mild	Moderate
DS-8	55	F	Frequent	VI	Mild	Moderate
DS-9	52	F	Frequent	VI	Mild	Severe
DS-10	56	M	Frequent	VI	Moderate	Mild
DS-11	56	F	Frequent	VI	Moderate	Mild
DS-12	49	M	Frequent	VI	Moderate	Mild
DS-13	55	M	Frequent	VI	Moderate	Mild
DS-14	46	M	Frequent	VI	Moderate	Moderate
DS-15	50	F	Frequent	VI	Severe	Moderate
DS-16	63	F	Frequent	VI	Severe	Moderate
DS-17	58	M	Frequent	VI	Severe	Severe
DS-18	54	M	Frequent	VI	Severe	Severe
Alzheimer's disease						
AD-1	85	M	Frequent	III/IV	None	None
AD-2	89	F	Frequent	VI	None	None
AD-3	91	M	Frequent	V	None	None
AD-4	77	M	Frequent	VI	None	Mild
AD-5	74	M	Frequent	VI	Mild	None
AD-6	67	F	Frequent	VI	Mild	None
AD-7	99	M	Frequent	V	Mild	None
AD-8	82	M	Frequent	VI	Mild	None
AD-9	91	F	Frequent	VI	Mild	None
AD-10	85	M	Frequent	VI	Mild	Mild
AD-11	62	M	Frequent	VI	Mild	Mid
AD-12	79	M	Frequent	VI	Mild	Mild
AD-13	84	M	Frequent	VI	Mild	Moderate
AD-14	77	M	Frequent	VI	Moderate	None
AD-15	88	M	Frequent	V	Moderate	Mild
AD-16	72	M	Frequent	VI	Severe	Moderate
AD-17	76	M	Frequent	V	Severe	Severe

A β 40, and A β 42 and are expressed as picomoles per gram of wet tissue weight. Samples were run in duplicates, including both diagnostic groups and both brain regions in each experiment. Each sample was analyzed at least twice and the mean of the two assays was used to determine final values for each sample/analyte.

³H-PiB Binding Assay

Unfractionated whole brain tissue homogenates (described above) were diluted from 300 mg/ml to a concentration 10 mg/ml in PBS prior to the binding assay as previously described (Ikonovic et al., 2008) with the exception of the fold-higher initial homogenate prepared in the current study. For determination of ³H-PiB binding, 1 nM ³H-PiB (American Radiolabeled Chemicals, St. Louis, MO, USA; specific activity 72.4 Ci/mmol) was incubated with 100 μ g tissue in 1 ml PBS as described previously (Ikonovic et al., 2008). Unlabeled PiB was dissolved in DMSO at 400 mM (to yield 51% DMSO) and this stock solution was diluted with PBS to achieve the desired concentration for the binding assay. Non-specific binding was

defined as the number of counts remaining in the presence of 1 mM unlabeled PiB. The binding mixtures were filtered through a Whatman GF/B glass filter using a Brandel M24R cell harvester (Brandel, Gaithersburg, MD) and rapidly washed five times with 3 ml PBS. The filters were counted in Cytoscint-ES after thorough vortex mixing and resting overnight. Results were corrected for non-specific, non-displaceable binding in the presence of 1 mM PiB and expressed as picomoles ³H-PiB bound per gram of wet brain tissue weight in the homogenate.

Statistical Analysis

Statistical analysis and graphs were performed using GraphPad PRISM Version 8 software (GraphPad, San Diego, CA, USA). The Kruskal-Wallis one-way analysis of variance was used to compare groups and pairwise comparisons were performed using Dunn's multiple comparisons post test. The Spearman rank order correlation test was used to assess associations between two variables. Demographic and diagnostic neuropathological characteristics in the DS group were compared to the AD group

using Student's *t*-test and chi-square tests where appropriate. Significance was set at $P < 0.05$.

RESULTS

Case Demographics and Neuropathological Characteristics

Individual case demographics and neuropathological characteristics are listed in **Table 1**. The DS group on average was younger than the AD group (DS: 53 ± 6 years; AD: 84 ± 10 years, $P < 0.001$; **Table 1**). Females were more represented in the DS group (nine females and nine males; 50%; $p < 0.01$) compared to the AD group (three females and 14 males; 18%).

The severity of AD neuropathological changes was similar between the two groups when compared by CERAD scores or by Braak staging, with all cases in the study having frequent neocortical neuritic plaques as well as neocortical stages of neurofibrillary pathology (Braak stages V or VI) with the exception of one AD case (AD-1) that was determined to be Braak stage III/IV (**Table 1**). The severity rating of CAA pathology was higher in the precuneus ($p = 0.0156$) and trended higher in the frontal cortex ($p = 0.1990$) in the DS group compared to the AD group (**Table 1**).


Diagnostic Group and Brain Region Comparisons: ^3H -PiB Binding, Unmodified A β 42 and A β 40, Pyroglutamate A β NpE3-42 and A β NpE3-40; Ratios of A β 42/A β 40 and A β NpE3-42/A β NpE3-40

in vitro ^3H -PiB binding levels in the frontal cortex and in the precuneus in the DS group did not differ from ^3H -PiB binding levels in the same regions, respectively, in the AD group (**Figure 1**, **Table 2**).

In both the frontal cortex and the precuneus, levels of unmodified A β 42 and pyroglutamate A β NpE3-42 were not statistically different between DS and AD groups (**Figures 2A–C**, **Table 2**). Unmodified A β 40 and pyroglutamate A β NpE3-40 levels in the frontal cortex and in the precuneus were significantly higher in the DS group compared to the AD group (**Figures 2B,D**, **Table 2**). The ratios of unmodified A β 42/A β 40 levels and pyroglutamate A β NpE3-42/A β NpE3-40 levels in the frontal cortex and in the precuneus were significantly lower in the DS group compared to the AD group (**Figures 3A,B**, **Table 2**).

Comparisons of Unmodified and Pyroglutamate-Modified A β Forms Within Each Brain Region in Each Diagnostic Group

In both the frontal cortex and the precuneus from the DS group, unmodified A β 42 and A β 40 were at similar levels and both were higher than A β NpE3-42 and A β NpE3-40 levels, which were also at similar levels in this group (**Table 2**). In the frontal cortex and in the precuneus from the AD group, unmodified A β 42 levels were higher



than A β 40, A β NpE3-40, and A β NpE3-42 levels, and both A β 40 and A β NpE3-42 levels were higher than A β NpE3-40 levels (**Table 2**).

Ratios of A β 42/A β NpE3-42 and A β 40/A β NpE3-40 in the DS Group Compared to the AD Group

In the DS group, the ratio of A β 42/A β NpE3-42 in the frontal cortex was higher, while in the precuneus the ratio trended higher, compared to the AD group (**Figure 3C**, **Table 2**). The ratio of A β 40/A β NpE3-40 levels in the precuneus was higher in the DS group compared to the AD group, while in the frontal cortex the ratio trended higher in the DS group (**Figure 3D**, **Table 2**).

Associations of Unmodified A β Levels With Pyroglutamate-Modified A β Levels, Both A β Forms With ^3H -PiB Binding Levels, and Both A β Forms and ^3H -PiB Binding Levels With CAA Severity in Down Syndrome and Alzheimer's Disease Groups


For correlation analyses within each diagnostic group, data from the frontal cortex and the precuneus were combined. We observed significant associations between levels of A β 42 and A β NpE3-42 and between levels of A β 40 and A β NpE3-40 in each diagnostic group (**Table 3**).

There was a significant association of unmodified A β 42 levels with ^3H -PiB levels in the DS group and a similar trend was present in the AD group (**Table 3**). No associations were observed between unmodified A β 40 levels and ^3H -PiB levels in either diagnostic group. We observed significant associations of A β NpE3-42 levels with ^3H -PiB levels in both diagnostic groups and a significant association of A β NpE3-40 levels with ^3H -PiB levels in the DS group but not in the AD group (**Table 3**).

TABLE 2 | Comparisons of ^3H -PIB, unmodified A β , pyroglutamate modified A β , and ratios of A β forms across groups/regions and with each other.

Variable	Down syndrome (frontal cortex)	Alzheimer's disease (frontal cortex)	Down syndrome (precuneus)	Alzheimer's disease (precuneus)	Kruskal–Wallis statistic and <i>P</i> value	Pairwise comparisons (<i>P</i> < 0.05)
^3H -PIB binding	152.2 \pm 55.60 (161.4)	158.5 \pm 59.94 (156.6)	135.1 \pm 63.1 (134.9)	143.4 \pm 60.86 (130.4)	1.35, <i>P</i> = 0.7128	n.s.
A β 42	1,428 \pm 373.2 (1,454)	1,274 \pm 411.5 (1,252)	1,461 \pm 534.3 (1,454)	1,119 \pm 549.8 (919.5)	6.39, <i>P</i> = 0.0943	n.s.
A β 40	2,868 \pm 2,940 (1,337)	655.5 \pm 893.0 (104.6)	5,149 \pm 6,091 (2,261)	227.5 \pm 404.5 (48.23)	28.46, <i>P</i> < 0.0001	FC-DS, PreC-DS > FC-AD, PreC-AD
A β NpE3-42	94.37 \pm 14.97 (91.74)	90.5 \pm 21.22 (90.49)	87.28 \pm 16.22 (86.46)	81.25 \pm 31.22 (83.25)	4.33, <i>P</i> = 0.2288	n.s.
A β NpE3-40	173 \pm 208.3 (51.63)	33.26 \pm 49.25 (8.38)	122.1 \pm 147 (48.71)	33.1 \pm 55.48 (5.88)	15.08, <i>P</i> = 0.0017	FC-DS, PreC-DS > FC-AD, PreC-AD
Kruskal–Wallis statistic and <i>P</i> value	47.65, <i>P</i> < 0.0001	32.63, <i>P</i> < 0.0001	41.83, <i>P</i> < 0.0001	36.40, <i>P</i> < 0.0001		
Pairwise comparisons (<i>P</i> < 0.05)	A β 42, A β 40 > A β NpE3-42, A β NpE3-40	A β 42 > A β 40, A β NpE3-42, A β NpE3-40; A β 40, A β NpE3-42 > A β NpE3-40	A β 42, A β 40 > A β NpE3-42, A β NpE3-40	A β 42 > A β 40, A β NpE3-40, A β NpE3-42; A β 40, A β NpE3-42 > A β NpE3-40		
A β 42/A β 40	1.69 \pm 1.82 (1.04)	13.29 \pm 17.29 (4.0)	2.05 \pm 3.05 (0.54)	43.44 \pm 51.0 (13.95)	20.73, <i>P</i> = 0.0001	FC-DS, PreC-DS > FC-AD, PreC-AD
A β NpE3-42/A β NpE3-40	2.69 \pm 3.05 (1.68)	18.98 \pm 19.32 (12.61)	4.554 \pm 6.939 (1.095)	29.37 \pm 29.07 (10.12)	13.36, <i>P</i> = 0.0035	FC-DS, PreC-DS > FC-AD, PreC-AD
A β 42/A β NpE3-42	16.01 \pm 2.12 (15.86)	13.92 \pm 4.40 (13.51)	15.83 \pm 4.22 (15.11)	14.50 \pm 8.37 (11.30)	10.0, <i>P</i> = 0.0185	FC-DS > FC-AD, PreC-AD
A β 40/A β NpE3-40	25.73 \pm 30.43 (18.72)	15.69 \pm 10.38 (13.02)	71.43 \pm 153.7 (33.16)	10.19 \pm 11.96 (8.48)	28.46, <i>P</i> < 0.0001	PreC-DS > FC-AD FC-DS > PreC-AD; PreC-DS > FC-AD, PreC-AD

Horizontal comparisons: A β NpE3-40, A β NpE3-42, and the A β NpE3-42/A β NpE3-40 ratio, A β 40, A β 42, and the A β 42/A β 40 ratio, and ^3H -PIB binding levels in Down syndrome compared to Alzheimer's disease in the frontal cortex and in the precuneus. Vertical comparisons: A β NpE3-40, A β NpE3-42, A β 40, and A β 42 levels separately in the frontal cortex (FC) and precuneus cortex (PreC) in Down syndrome and in Alzheimer's disease. Units are pmol/g tissue wet weight and arithmetic means \pm standard deviations and medians are shown. Comparisons were made using the Kruskal–Wallis one-way analysis of variance with Dunn's post test for multiple comparisons.



No associations were observed between the ratio of unmodified A β forms and $^3\text{H-PiB}$ levels in either diagnostic group. There was a significant association of the ratio A β NpE3-42/A β NpE3-40 with $^3\text{H-PiB}$ levels in the DS group but not in the AD group (Table 3).


In both diagnostic groups, there were significant associations of A β 40 and A β NpE3-40 levels with CAA severity and of ratios A β 42/A β 40 and A β NpE3-42/A β NpE3-40 with CAA severity (Table 3). Greater CAA severity correlated with higher $^3\text{H-PiB}$ binding levels in the DS group, but not in the AD group (Table 3).

DISCUSSION

The extent of interaction between PiB, or related amyloid-binding radiopharmaceuticals for PET imaging, with different unmodified A β forms or post-translationally truncated and pyroglutamate-modified A β forms in pathological amyloid deposits in cortical regions from DS and AD brains is not well understood. Better characterization of these interactions could facilitate the interpretation of amyloid PET imaging studies and identify targets for therapy. DS patients develop amyloid pathology and are likely to show positive amyloid PET scans,

by age 40. Since the pyroglutamate modification is believed to drive A β fibrillization and deposition in amyloid plaques (Jawhar et al., 2011), in the present study we undertook a quantitative ELISA analysis of insoluble (fibrillar) pools of unmodified A β 42 and A β 40 forms as well as N-terminus truncated and pyroglutamate-modified A β NpE3-42 and A β NpE3-40 forms in the frontal cortex and the precuneus from adult DS cases compared to a group of sporadic AD cases with similar levels of neocortical neuritic plaques and neurofibrillary tangle pathology. Additionally, we assayed $^3\text{H-PiB}$ binding levels in the same homogenates used for the ELISA studies. We found that in both the frontal cortex and the precuneus regions, A β 42, A β NpE3-42, and $^3\text{H-PiB}$ binding levels did not differ significantly between the two diagnostic groups. In contrast, DS cases had significantly higher A β 40 and A β NpE3-40 levels, and lower A β 42/A β 40 and A β NpE3-42/A β NpE3-40 ratios in these cortical regions, compared to AD cases.

Genetic predisposition for premature pathological aging with early-onset of A β plaque accumulation in DS relative to sporadic AD (Teller et al., 1996; Mori et al., 2002; Zigman et al., 2002, 2008) could result in a greater abundance of fibrillar A β deposits in brains of adults with DS when compared to individuals in the



early stages of AD. In agreement with this, we previously reported higher levels of insoluble unmodified A β 42, and a greater burden of mature amyloid plaques, in the frontal cortex from adult individuals with DS (age range: 43–63 years) compared to cases with mild-moderate AD from the Rush Religious Order Study (age range: 77–101 years; Abrahamson et al., 2019). In contrast, our current study demonstrated that in cases from the same DS cohort, neocortical levels of insoluble unmodified A β 42 were not different from a group of late-stage AD cases in our ADRC autopsy cohort (age range: 62–99 years). Cortical levels of insoluble pyroglutamate A β NpE3-42 were also similar between the DS group and the late stage AD group in the current study. The propensity for the A β forms ending at amino acid 42 to aggregate into amyloid fibrils and deposit early in the process of amyloid plaque formation could explain these observations. Specifically, our DS subjects were above the age of 40 years and exhibited a high level of amyloid plaque pathology

by CERAD scores for neocortical neuritic plaques that were similar to late-stage AD (Wisniewski et al., 1985; Mann and Esiri, 1989), thus it is possible that levels of fibrillar A β x-42 forms reach a plateau early in the pathological progression of DS and AD. In contrast, A β x-40 forms clearly distinguished DS and AD groups in our current study; in both cortical regions examined, we observed significantly higher levels of A β 40 and A β NpE3-40 in the DS group compared to the late-stage AD group and, as a result, DS cases had lower ratios of A β 42/40 and A β NpE3-42/A β NpE3-40 when compared to late-stage AD cases. Higher levels of A β 40 and A β NpE3-40 in the frontal cortex of DS cases compared to AD cases were also reported in a study of five DS individuals (age range: 53–67) and 14 AD cases (age 66–86; Hosoda et al., 1998). Another major finding of our current study is that compared to AD, the DS group had lower proportions of pyroglutamate relative to unmodified A β forms. This could be explained by a shorter residence time

TABLE 3 | Associations of unmodified A β levels with pyroglutamate-modified A β levels, both A β forms with ^3H -PiB binding levels, and both A β forms with CAA severity in Down syndrome and Alzheimer's disease groups.

Comparison/Group	Down syndrome	Alzheimer's disease
Unmodified Aβ to pyroglutamate-modified Aβ (same C-terminus)	Spearman <i>r</i> (P value)	Spearman <i>r</i> (P value)
A β 42 and A β NpE3-42	<i>0.5476 (0.0014)</i>	<i>0.6408 (<0.0001)</i>
A β 40 and A β NpE3-40	<i>0.8292 (<0.0001)</i>	<i>0.8626 (<0.0001)</i>
Aβ forms to ^3H-PiB	Spearman <i>r</i> (P value)	Spearman <i>r</i> (P value)
A β 42 and ^3H -PiB	<i>0.4197 (0.0135)</i>	<i>0.2852 (0.1337)</i>
A β 40 and ^3H -PiB	<i>0.2825 (0.1055)</i>	<i>-0.0097 (0.9588)</i>
A β NpE3-42 and ^3H -PiB	<i>0.3661 (0.0428)</i>	<i>0.4459 (0.0135)</i>
A β NpE3-40 and ^3H -PiB	<i>0.4377 (0.0122)</i>	<i>-0.0269 (0.8877)</i>
A β 42/A β 40 ratio and ^3H -PiB	<i>-0.2610 (0.1360)</i>	<i>0.2717 (0.1704)</i>
A β NpE3-42/A β NpE3-40 and ^3H -PiB	<i>-0.5097 (0.0047)</i>	<i>0.0631 (0.7452)</i>
Aβ forms and ^3H-PiB to CAA severity	Spearman <i>r</i> (P value)	Spearman <i>r</i> (P value)
A β 42 and CAA severity	<i>0.4088 (0.0164)</i>	<i>-0.2090 (0.2766)</i>
A β 40 and CAA severity	<i>0.7786 (<0.0001)</i>	<i>0.5397 (0.0017)</i>
A β NpE3-42 and CAA severity	<i>-0.0092 (0.9608)</i>	<i>-0.4759 (0.0079)</i>
A β NpE3-40 and CAA severity	<i>0.7672 (<0.0001)</i>	<i>0.3273 (0.0474)</i>
A β 42/A β 40 and CAA severity	<i>-0.7739 (<0.0001)</i>	<i>-0.5134 (0.0062)</i>
A β NpE3-42/A β NpE3-40 and CAA severity	<i>-0.8394 (<0.0001)</i>	<i>-0.4108 (0.0269)</i>
^3H -PiB and CAA severity	<i>0.3391 (0.0498)</i>	<i>-0.0419 (0.8141)</i>

For each correlation analysis, data from the frontal cortex and the precuneus were combined. The Spearman rank order correlation test was used to examine associations among variables. Associations meeting criteria for significance ($P < 0.05$) are italicized.

of A β deposits in DS brains when compared to brains of older sporadic AD cases with end-stage pathology. Different proportions of pyroglutamate-modified A β and unmodified A β in DS compared to preclinical (pathological aging) and clinical AD might affect their detection by amyloid PET. This could have influenced the findings of a longitudinal ^{11}C -PiB PET study which reported slower progression of the frontal cortex and precuneus amyloid pathology in nondemented young adults with DS (mean age 37 years) when compared to nondemented elderly (mean age 73 years; Tudorascu et al., 2019). In contrast to our findings, Hosoda and colleagues reported higher levels of A β NpE3-42 compared to unmodified A β 1-42 in their DS group (Hosoda et al., 1998). The small number of DS cases and large individual variability of pyroglutamate-modified A β levels in the latter report make it difficult to explain this discrepancy.

The preponderance of A β 40 levels in unmodified and pyroglutamate-modified forms in our DS group appears to be influenced by greater severity of CAA, despite comparable levels of mature amyloid plaques (frequent neocortical neuritic plaques) in the DS and AD groups. This is supported by our observations that levels of A β 40 and A β NpE3-40 forms (and ratios of A β 42/A β 40 and A β NpE3-42/A β NpE3-40) were associated strongly with CAA severity in the DS group, while in the AD group these associations were much weaker. Previous studies reported that CAA is a significant contributor to the neuropathology of DS and is observed more frequently in DS adults over 45-50 years of age than in people with sporadic AD and normal elderly controls (Vinters, 1987; Wilcock et al., 2016; Carmona-Iragui et al., 2017; Head et al., 2017; Davidson et al., 2018). Our results are also consistent with studies reporting that A β 40 is the primary constituent of vascular amyloid in AD and DS (Miller et al., 1993; Iwatsubo et al., 1995; Harigaya et al.,

2000; Guntert et al., 2006; Mann et al., 2018; Gkanatsiou et al., 2019).

We observed that DS and late-stage AD groups had similar levels of ^3H -PiB binding in the frontal cortex and in the precuneus. Although DS cases had higher levels of A β forms ending at carboxy terminus amino acid 40 and greater severity of CAA, which correlated strongly with greater ^3H -PiB binding, the lack of differences in ^3H -PiB binding between DS and AD groups appears to be influenced more by these two groups having similar levels of unmodified and pyroglutamate-modified A β 42 forms. This is in agreement with observations from PiB PET imaging-autopsy studies of AD and *in vitro* analyses of synthetic A β that PiB binding is influenced primarily by the A β 42 form (Ikonovic et al., 2008, 2020; Yamin and Teplow, 2017) which was reported as the initial and dominant A β form in amyloid plaques in AD and DS (Miller et al., 1993; Iwatsubo et al., 1994, 1995, 1996; Lemere et al., 1996). Interestingly, the strongest correlate of (higher) ^3H -PiB binding was the (lower) ratio of insoluble A β NpE3-42/A β NpE3-40 in DS, but not in the AD group. However, higher levels of insoluble A β NpE3-40 and A β 40, as well as greater severity of CAA, do not appear to be the main determinants of ^3H -PiB binding levels in DS cases when the overall parenchymal plaque pathology burden is high.

Several potential limitations should be considered in the current study. The commercial ELISA kits we used for the detection of unmodified A β forms have been widely applied and reported in published studies. The specificity of their N-terminus (detection) antibody is defined in the range of A β amino acids 1-16, and this overlaps the range recognized by the well-characterized monoclonal IgG clone 6E10 (Kim et al., 1990). Thus, we cannot be confident that these kits measure

exclusively the intact “full-length” A β 1–40 and A β 1–42 forms, because theoretically, they could detect some A β forms truncated at the proximal portion of the *N*-terminus. However, *N*-terminus truncated and pyroglutamate-modified forms of A β likely undergo additional molecular and conformational modifications and this could interfere with the binding of *N*-terminus-directed antibodies to epitopes that overlap, or are near to, the pyroglutamate modification. Secondly, consistent with brain tissue sampling in a previous analysis of unmodified and pyroglutamate-modified A β concentrations in DS and AD (Hosoda et al., 1998), cortical samples in our study were stripped of the leptomeningeal vessels but they included intraparenchymal vasculature, so the ELISA and ³H-PiB binding assays measured insoluble A β from the combined pool of amyloid plaques as well as capillary and arterial CAA. This approach is consistent with ¹¹C-PiB PET and related amyloid PET radioligands lacking selectivity to distinguish A β plaques from CAA (Bacskai et al., 2007; Johnson et al., 2007; Lockhart et al., 2007; Dierksen et al., 2010; Ly et al., 2010; Sabbagh et al., 2011; Ducharme et al., 2013; Murray et al., 2015; Seo et al., 2017; Charidimou et al., 2018; Planton et al., 2020). Further studies will require biochemical analyses of unmodified and pyroglutamate-modified A β forms and ³H-PiB binding in isolated microvessels compared to vessel-free brain parenchyma extracts from DS brains as has been done previously in samples from AD brains (Roher et al., 1993; Kuo et al., 1997; Bourassa et al., 2019) as well as isolated plaque cores in both diagnostic groups to extend previous studies (Allsop et al., 1986; Roher et al., 1993). Lastly, as in most brain banks, the frozen tissue samples for biochemical assays and fixed tissue samples for neuropathological workup were not from the same hemisphere. We assumed, in this study, that neuropathological findings from one hemisphere informed us about the overall brain pathology including the opposite hemisphere from which our samples for ELISA and ³H-PiB binding assays were obtained.

In summary, our study demonstrates that compared to late-stage AD cases, older adults with DS have similar levels of ³H-PiB binding in the frontal cortex and in the precuneus. This is consistent with the observation that both groups had frequent neocortical neuritic plaques and similar levels of A β 42 and A β NpE3-42 forms in these brain regions. The DS group had more severe CAA pathology and significantly higher levels of A β 40 and A β NpE3-40 forms in the same cortical regions, however, this was not the key determinant of PiB binding. The presence of CAA is significant because it can impact clinical presentation. For example, CAA independently affects cognition, and when present in conjunction with AD pathology it can result in more severe cognitive impairment (Pfeifer et al., 2002). Interestingly, while the cerebrovascular disease is considered a “second hit” that contributes to the clinical manifestation of AD (Provenzano et al., 2013), DS individuals may have a predisposition that protects against cardiovascular risk factors (Murdoch et al., 1977; Pucci et al., 2016; Lott and Head, 2019), but this protection may be offset by the development of severe CAA pathology in the DS brain. PiB binds to fibrillar A β in both parenchymal and vascular (CAA)

deposits, and these two pathologies cannot be distinguished unequivocally on amyloid PET using PiB or related amyloid-binding radioligands (Bacskai et al., 2007; Lockhart et al., 2007; Dierksen et al., 2010; Sabbagh et al., 2011; Ducharme et al., 2013). Instead, the presence of CAA in the clinical setting is suspected only if there is a predominance of occipital signal on amyloid PET scans (Johnson et al., 2007; Greenberg et al., 2008; Seo et al., 2017) and higher frequencies of microbleeds, hemorrhagic lesions, or ischemic lesions detected by MR imaging (Dierksen et al., 2010; Ly et al., 2010; Viswanathan and Greenberg, 2011; Yamada, 2015). PET radiotracers selective for CAA are still under development (Abrahamson et al., 2021) and will be critical to incorporate into the neuroimaging biomarker panel for DS, to monitor A β deposition in the cerebral vasculature relative to PET measures of total (parenchymal and vascular) amyloid.

DATA AVAILABILITY STATEMENT

The datasets generated in the current study are available from the corresponding author on reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Institutional Review Board and the Committee for Oversight of Research and Clinical Training Involving Decedents, University of Pittsburgh and University of California, Irvine. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

EA, VV, BH, IL, EH, and MI contributed to the design and implementation of the research. VP, TR, EA, VV, and MI contributed to the analysis of the results. All authors contributed to the writing of the manuscript.

FUNDING

This work was supported by National Institutes of Health (NIH) grants U19 AG068054, U01 AG051406, R01 AG052528, P01 AG025204, and P01 AG014449. The UCI ADRC is funded by NIH/NIA Grant P50 AG16573. The University of Pittsburgh Alzheimer’s Disease Research Center is funded by NIH/NIA Grant P30 AG066468.

ACKNOWLEDGMENTS

³H-PiB was provided by Dr. Chester A. Mathis and Dr. William E. Klunk. The authors wish to thank William R. Paljug, Manik L. Debnath, and Ryan J. Marsden.

REFERENCES

- Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., et al. (2019). Neuropathological correlates of amyloid PET imaging in Down syndrome. *Dev. Neurobiol.* 79, 750–766. doi: 10.1002/dneu.22713
- Abrahamson, E. E., Kruszka, G. I., Mi, Z. R. P. W., Debnath, M. L., Klunk, W. E., Mufson, E. J., et al. (2016). Pyroglutamate and full-length amyloid-B concentrations in the superior frontal cortex across clinical stages of Alzheimer's disease. *Alzheimers Dement.* 12, P742–P743. doi: 10.1016/j.jalz.2016.06.1548
- Abrahamson, E. E., Stehouwer, J. S., Vazquez, A. L., Huang, G. F., Mason, N. S., Lopresti, B. J., et al. (2021). Development of a PET radioligand selective for cerebral amyloid angiopathy. *Nucl. Med. Biol.* 92, 85–96. doi: 10.1016/j.nucmedbio.2020.05.001
- Akiyama, H., Mori, H., Sahara, N., Kondo, H., Ikeda, K., Nishimura, T., et al. (1997). Variable deposition of amyloid β -protein (A β) with the carboxy-terminus that ends at residue valine40 (A β 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specific for a β 40 and the A β that ends at residues alanine42/threonine43 (A β 42). *Neurochem. Res.* 22, 1499–1506. doi: 10.1023/a:1021910729963
- Allsop, D., Kidd, M., Landon, M., and Tomlinson, A. (1986). Isolated senile plaque cores in Alzheimer's disease and Down's syndrome show differences in morphology. *J. Neurol. Neurosurg Psychiatry* 49, 886–892. doi: 10.1136/jnnp.49.8.886
- Annus, T., Wilson, L. R., Acosta-Cabronero, J., Cardenas-Blanco, A., Hong, Y. T., Fryer, T. D., et al. (2017). The Down syndrome brain in the presence and absence of fibrillar β -amyloidosis. *Neurobiol. Aging* 53, 11–19. doi: 10.1016/j.neurobiolaging.2017.01.009
- Annus, T., Wilson, L. R., Hong, Y. T., Acosta-Cabronero, J., Fryer, T. D., Cardenas-Blanco, A., et al. (2016). The pattern of amyloid accumulation in the brains of adults with down syndrome. *Alzheimers Dement.* 12, 538–545. doi: 10.1016/j.jalz.2015.07.490
- Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., Schneider, J. A., et al. (2011). Cerebral amyloid angiopathy pathology and cognitive domains in older persons. *Ann. Neurol.* 69, 320–327. doi: 10.1002/ana.22112
- Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., et al. (2007). Molecular imaging with pittsburgh compound b confirmed at autopsy: a case report. *Arch. Neurol.* 64, 431–434. doi: 10.1001/archneur.64.3.431
- Bourassa, P., Tremblay, C., Schneider, J. A., Bennett, D. A., and Calon, F. (2019). β -amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease. *Acta Neuropathol.* 137, 801–823. doi: 10.1007/s00401-019-01967-4
- Braak, H., Alafuzoff, I., Arzberger, T., Kretschmar, H., and Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.* 112, 389–404. doi: 10.1007/s00401-006-0127-z
- Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259. doi: 10.1007/BF00308809
- Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid and memory. *J. Neurosci.* 25, 7709–7717. doi: 10.1523/JNEUROSCI.2177-05.2005
- Carmona-Iragui, M., Balasa, M., Benjam, B., Alcolea, D., Fernandez, S., Videla, L., et al. (2017). Cerebral amyloid angiopathy in down syndrome and sporadic and autosomal-dominant Alzheimer's disease. *Alzheimers Dement.* 13, 1251–1260. doi: 10.1016/j.jalz.2017.03.007
- Charidimou, A., Farid, K., Tsai, H. H., Tsai, L. K., Yen, R. F., Baron, J. C., et al. (2018). Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. *J. Neurol. Neurosurg. Psychiatry* 89, 410–417. doi: 10.1136/jnnp-2017-316851
- Chen, G. F., Xu, T. H., Yan, Y., Zhou, Y. R., Jiang, Y., Melcher, K., et al. (2017). Amyloid β : structure, biology and structure-based therapeutic development. *Acta Pharmacol. Sin.* 38, 1205–1235. doi: 10.1038/aps.2017.28
- Cody, K. A., Piro-Gambetti, B., Zammit, M. D., Christian, B. T., Handen, B. L., Klunk, W. E., et al. (2020). Association of sleep with cognition and β amyloid accumulation in adults with down syndrome. *Neurobiol. Aging* 93, 44–51. doi: 10.1016/j.neurobiolaging.2020.04.018
- Cohen, A. D., McDade, E., Christian, B., Price, J., Mathis, C., Klunk, W., et al. (2018). Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. *Alzheimers Dement.* 14, 743–750. doi: 10.1016/j.jalz.2018.01.002
- Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., and Ikonomic, M. D. (2012). Using Pittsburgh Compound B for *in vivo* PET imaging of fibrillar amyloid- β . *Adv. Pharmacol.* 64, 27–81. doi: 10.1016/B978-0-12-394816-8.00002-7
- Cole, J. H., Annus, T., Wilson, L. R., Remtulla, R., Hong, Y. T., Fryer, T. D., et al. (2017). Brain-predicted age in Down syndrome is associated with β amyloid deposition and cognitive decline. *Neurobiol. Aging* 56, 41–49. doi: 10.1016/j.neurobiolaging.2017.04.006
- Creekmore, B. C., Chang, Y. W., and Lee, E. B. (2021). The cryo-EM effect: structural biology of neurodegenerative disease aggregates. *J. Neuropathol. Exp. Neurol.* 80, 514–529. doi: 10.1093/jnen/nlab039
- Cynis, H., Scheel, E., Saido, T. C., Schilling, S., and Demuth, H. U. (2008). Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid- β . *Biochemistry* 47, 7405–7413. doi: 10.1021/bi800250p
- Dammers, C., Schwarten, M., Buell, A. K., and Willbold, D. (2017). Pyroglutamate-modified A β (3–42) affects aggregation kinetics of A β (1–42) by accelerating primary and secondary pathways. *Chem. Sci.* 8, 4996–5004. doi: 10.1039/c6sc04797a
- Davidson, Y. S., Robinson, A., Prasher, V. P., and Mann, D. M. A. (2018). The age of onset and evolution of braak tangle stage and thal amyloid pathology of Alzheimer's disease in individuals with down syndrome. *Acta Neuropathol. Commun.* 6:56. doi: 10.1186/s40478-018-0559-4
- Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., et al. (2012). A plaque-specific antibody clears existing β -amyloid plaques in Alzheimer's disease mice. *Neuron* 76, 908–920. doi: 10.1016/j.neuron.2012.10.029
- Dickson, D. W. (2005). Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. *Acta Neuropathol.* 109, 14–24. doi: 10.1007/s00401-004-0950-z
- Dickson, D. W. (1997). The pathogenesis of senile plaques. *J. Neuropathol. Exp. Neurol.* 56, 321–339. doi: 10.1097/00005072-199704000-00001
- Dierksen, G. A., Skehan, M. E., Khan, M. A., Jeng, J., Nandigam, R. N., Becker, J. A., et al. (2010). Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. *Ann. Neurol.* 68, 545–548. doi: 10.1002/ana.22099
- Ducharme, S., Guiot, M. C., Nikelski, J., and Chertkow, H. (2013). Does a positive pittsburgh compound B scan in a patient with dementia equal Alzheimer disease? *JAMA Neurol.* 70, 912–914. doi: 10.1001/jamaneurol.2013.420
- Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., et al. (2013). Pyroglutamate-3 amyloid- β deposition in the brains of humans, non-human primates, canines and Alzheimer disease-like transgenic mouse models. *Am. J. Pathol.* 183, 369–381. doi: 10.1016/j.ajpath.2013.05.005
- Frost, J. L., Liu, B., Rahfeld, J. U., Kleinschmidt, M., O'Nuallain, B., Le, K. X., et al. (2015). An anti-pyroglutamate-3 A β vaccine reduces plaques and improves cognition in APPsw/PS1DeltaE9 mice. *Neurobiol. Aging* 36, 3187–3199. doi: 10.1016/j.neurobiolaging.2015.08.021
- Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., et al. (2019). A distinct brain β amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. *Neurosci. Lett.* 701, 125–131. doi: 10.1016/j.neulet.2019.02.033
- Gkanatsiou, E., Sahlin, C., Portelius, E., Johannesson, M., Soderberg, L., Falting, J., et al. (2021). Characterization of monomeric and soluble aggregated A β in Down's syndrome and Alzheimer's disease brains. *Neurosci. Lett.* 754:135894. doi: 10.1016/j.neulet.2021.135894
- Golde, T. E., Eckman, C. B., and Younkin, S. G. (2000). Biochemical detection of A β isoforms: implications for pathogenesis, diagnosis and treatment of

- Alzheimer's disease. *Biochim. Biophys. Acta* 1502, 172–187. doi: 10.1016/s0925-4439(00)00043-0
- Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., and Otvos, L. Jr. (1995). Amyloid β protein (A β) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at a β 40 or A β 42(43). *J. Biol. Chem.* 270, 7013–7016. doi: 10.1186/s40478-021-01225-3
- Greenberg, S. M., Grabowski, T., Gurol, M. E., Skehan, M. E., Nandigam, R. N., Becker, J. A., et al. (2008). Detection of isolated cerebrovascular β -amyloid with Pittsburgh compound B. *Ann. Neurol.* 64, 587–591. doi: 10.1002/ana.21528
- Gunn, A. P., Masters, C. L., and Cherny, R. A. (2010). Pyroglutamate-A β : role in the natural history of Alzheimer's disease. *Int. J. Biochem. Cell Biol.* 42, 1915–1918. doi: 10.1016/j.biocel.2010.08.015
- Guntert, A., Dobeli, H., and Bohrmann, B. (2006). High sensitivity analysis of amyloid- β peptide composition in amyloid deposits from human and PS2APP mouse brain. *Neuroscience* 143, 461–475. doi: 10.1016/j.neuroscience.2006.08.027
- Handen, B. L., Cohen, A. D., Channamalappa, U., Bulova, P., Cannon, S. A., Cohen, W. I., et al. (2012). Imaging brain amyloid in nondemented young adults with Down syndrome using pittsburgh compound B. *Alzheimers Dement.* 8, 496–501. doi: 10.1016/j.jalz.2011.09.229
- Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N. S. O. B., Mapstone, M., Fagan, A. M., et al. (2020). The Alzheimer's biomarker consortium-down syndrome: rationale and methodology. *Alzheimers Dement. (Amst)* 12:e12065. doi: 10.1002/dad2.12065
- Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C. M., Shoji, M., and Younkin, S. G. (2000). Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochem. Biophys. Res. Commun.* 276, 422–427. doi: 10.1006/bbrc.2000.3490
- Hartley, S. L., Handen, B. L., Devenny, D., Mihaila, I., Hardison, R., Lao, P. J., et al. (2017). Cognitive decline and brain amyloid- β accumulation across 3 years in adults with down syndrome. *Neurobiol. Aging* 58, 68–76. doi: 10.1016/j.neurobiolaging.2017.05.019
- Hartley, S. L., Handen, B. L., Devenny, D., Tudorascu, D., Piro-Gambetti, B., Zammit, M. D., et al. (2020). Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. *Alzheimers Dement. (Amst)* 12:e12096. doi: 10.1002/dad2.12096
- Hartley, S. L., Handen, B. L., Devenny, D. A., Hardison, R., Mihaila, I., Price, J. C., et al. (2014). Cognitive functioning in relation to brain amyloid- β in healthy adults with Down syndrome. *Brain* 137, 2556–2563. doi: 10.1093/brain/awu173
- He, W., and Barrow, C. J. (1999). The A β 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β -sheet forming and aggregation propensities *in vitro* than full-length A β . *Biochemistry* 38, 10871–10877. doi: 10.1021/bi990563r
- Head, E., and Ances, B. (2020). Biomarkers in down syndrome can help us understand Alzheimer's disease. *Lancet* 395, 1951–1953. doi: 10.1016/S0140-6736(20)30916-8
- Head, E., Lott, I. T., Wilcock, D. M., and Lemere, C. A. (2016). Aging in down syndrome and the development of Alzheimer's disease neuropathology. *Curr. Alzheimer Res.* 13, 18–29. doi: 10.2174/1567205012666151020114607
- Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., et al. (2017). Cerebrovascular pathology in down syndrome and Alzheimer disease. *Acta Neuropathol. Commun.* 5:93. doi: 10.1186/s40478-017-0499-4
- Hendrix, J. A., Airey, D. C., Britton, A., Burke, A. D., Capone, G. T., Chavez, R., et al. (2021). Cross-sectional exploration of plasma biomarkers of Alzheimer's disease in down syndrome: early data from the longitudinal investigation for enhancing down syndrome research (LIFE-DSR) study. *J. Clin. Med.* 10:1907. doi: 10.3390/jcm10091907
- Hosoda, R., Saido, T. C., Otvos, L. Jr., Arai, T., Mann, D. M., Lee, V. M., et al. (1998). Quantification of modified amyloid β peptides in Alzheimer disease and Down syndrome brains. *J. Neuropathol. Exp. Neurol.* 57, 1089–1095. doi: 10.1097/00005072-199811000-00012
- Ikonovic, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J. K., Mathis, C. A., Klunk, W. E., et al. (2020). Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. *Acta Neuropathol.* 140, 463–476. doi: 10.1007/s00401-020-02175-1
- Ikonovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., et al. (2008). Post-mortem correlates of *in vivo* PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain* 131, 1630–1645. doi: 10.1093/brain/awn016
- Iwatsubo, T., Mann, D. M., Odaka, A., Suzuki, N., and Ihara, Y. (1995). Amyloid β protein (A β) deposition: a β 42(43) precedes A β 40 in Down syndrome. *Ann. Neurol.* 37, 294–299. doi: 10.1002/ana.410370305
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., et al. (1994). Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: evidence that an initially deposited species is A β 42 (43). *Neuron* 13, 45–53. doi: 10.1016/0896-6273(94)90458-8
- Iwatsubo, T., Saido, T. C., Mann, D. M., Lee, V. M., and Trojanowski, J. Q. (1996). Full-length amyloid- β (1–42(43)) and amino-terminally modified and truncated amyloid- β 42(43) deposit in diffuse plaques. *Am. J. Pathol.* 149, 1823–1830.
- Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* 32, 4693–4697. doi: 10.1021/bi00069a001
- Jawhar, S., Wirths, O., and Bayer, T. A. (2011). Pyroglutamate amyloid- β (A β): a hatchet man in Alzheimer disease. *J. Biol. Chem.* 286, 38825–38832. doi: 10.1074/jbc.R111.288308
- Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., et al. (2007). Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. *Ann. Neurol.* 62, 229–234. doi: 10.1002/ana.21164
- Jones, D. T., Machulda, M. M., Vemuri, P., McDade, E. M., Zeng, G., Senjem, M. L., et al. (2011). Age-related changes in the default mode network are more advanced in Alzheimer disease. *Neurology* 77, 1524–1531. doi: 10.1212/WNL.0b013e318233b33d
- Kim, K. S., Wen, G. Y., Bancher, C., Chen, C. M. J., Sapienza, V. J., Hong, H., et al. (1990). Detection, quantitation of amyloid β -peptide with 2 monoclonal antibodies. *Neurosci. Res. Commun.* 7, 113–122.
- Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B. *Ann. Neurol.* 55, 306–319. doi: 10.1002/ana.20009
- Kuo, Y. M., Emmerling, M. R., Woods, A. S., Cotter, R. J., and Roher, A. E. (1997). Isolation, chemical characterization and quantitation of A β 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. *Biochem. Biophys. Res. Commun.* 237, 188–191. doi: 10.1006/bbrc.1997.7083
- Landt, J., D'Abbrera, J. C., Holland, A. J., Aigbirhio, F. I., Fryer, T. D., Canales, R., et al. (2011). Using positron emission tomography and Carbon 11-labeled pittsburgh compound B to image brain fibrillar β -amyloid in adults with down syndrome: safety, acceptability and feasibility. *Arch. Neurol.* 68, 890–896. doi: 10.1001/archneurol.2011.36
- Lao, P. J., Betthausen, T. J., Hillmer, A. T., Price, J. C., Klunk, W. E., Mihaila, I., et al. (2016). The effects of normal aging on amyloid- β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled pittsburgh compound B. *Alzheimers Dement.* 12, 380–390. doi: 10.1016/j.jalz.2015.05.013
- Lao, P. J., Handen, B. L., Betthausen, T. J., Mihaila, I., Hartley, S. L., Cohen, A. D., et al. (2018). Alzheimer-like pattern of hypometabolism emerges with elevated amyloid- β burden in down syndrome. *J. Alzheimers Dis.* 61, 631–644. doi: 10.3233/JAD-170720
- Lao, P. J., Handen, B. L., Betthausen, T. J., Mihaila, I., Hartley, S. L., Cohen, A. D., et al. (2017). Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented down syndrome population. *Alzheimers Dement. (Amst)* 9, 1–9. doi: 10.1016/j.dadm.2017.05.001
- Lemere, C. A., Bluszajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., Selkoe, D. J., et al. (1996). Sequence of deposition of heterogeneous amyloid β -peptides and APOE in down syndrome: implications for initial events in amyloid plaque formation. *Neurobiol. Dis.* 3, 16–32. doi: 10.1006/nbdi.1996.0003
- LeVine, H. 3rd, Spielmann, H. P., Matveev, S., Cauvi, F. M., Murphy, M. P., Beckett, T. L., et al. (2017). Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan. *Neurobiol. Aging* 54, 163–169. doi: 10.1016/j.neurobiolaging.2017.03.005

- Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., et al. (2007). PIB is a non-specific imaging marker of amyloid- β (A β) peptide-related cerebral amyloidosis. *Brain* 130, 2607–2615. doi: 10.1093/brain/awm191
- Lott, I. T., and Head, E. (2019). Dementia in down syndrome: unique insights for Alzheimer disease research. *Nat. Rev. Neurol.* 15, 135–147. doi: 10.1038/s41582-018-0132-6
- Ly, J. V., Donnan, G. A., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G., et al. (2010). 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. *Neurology* 74, 487–493. doi: 10.1212/WNL.0b013e3181cef7e3
- Mak, E., Bickerton, A., Padilla, C., Walpert, M. J., Annus, T., Wilson, L. R., et al. (2019a). Longitudinal trajectories of amyloid deposition, cortical thickness and tau in Down syndrome: a deep-phenotyping case report. *Alzheimers Dement. (Amst)* 11, 654–658. doi: 10.1016/j.dadm.2019.04.006
- Mak, E., Padilla, C., Annus, T., Wilson, L. R., Hong, Y. T., Fryer, T. D., et al. (2019b). Delineating the topography of amyloid-associated cortical atrophy in Down syndrome. *Neurobiol. Aging* 80, 196–202. doi: 10.1016/j.neurobiolaging.2019.02.018
- Mann, D. M., and Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. *J. Neurol. Sci.* 89, 169–179. doi: 10.1016/0022-510x(89)90019-1
- Mann, D. M., and Iwatsubo, T. (1996). Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42 (43). *Neurodegeneration* 5, 115–120. doi: 10.1006/neur.1996.0017
- Mann, D. M. (1988). Alzheimer's disease and Down's syndrome. *Histopathology* 13, 125–137. doi: 10.1111/j.1365-2559.1988.tb02018.x
- Mann, D. M. A., Davidson, Y. S., Robinson, A. C., Allen, N., Hashimoto, T., Richardson, A., et al. (2018). Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. *Acta Neuropathol.* 136, 569–587. doi: 10.1007/s00401-018-1866-3
- Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., Beyreuther, K., et al. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. U S A* 82, 4245–4249. doi: 10.1073/pnas.82.12.4245
- Mathis, C. A., Lopresti, B. J., Ikonomic, M. D., and Klunk, W. E. (2017). Small-molecule PET tracers for imaging proteinopathies. *Semin. Nucl. Med.* 47, 553–575. doi: 10.1053/j.semnuclmed.2017.06.003
- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. *Neurology* 34, 939–944. doi: 10.1212/wnl.34.7.939
- Michno, W., Nystrom, S., Wehrli, P., Lashley, T., Brinkmalm, G., Guerard, L., et al. (2019). Pyroglutamation of amyloid-beta42 (Abeta42) followed by Abeta140 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. *J. Biol. Chem.* 294, 6719–6732. doi: 10.1074/jbc.RA118.006604
- Mihaila, I., Handen, B. L., Christian, B. T., Lao, P. J., Cody, K. A., Klunk, W. E., et al. (2019). Leisure activity, brain beta-amyloid and episodic memory in adults with Down syndrome. *Dev. Neurobiol.* 79, 738–749. doi: 10.1002/dneu.22677
- Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., et al. (1993). Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. *Arch. Biochem. Biophys.* 301, 41–52. doi: 10.1006/abbi.1993.1112
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., et al. (2021). Donanemab in early Alzheimer's disease. *N. Engl. J. Med.* 384, 1691–1704. doi: 10.1056/NEJMoa2100708
- Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., et al. (1991). The consortium to establish a registry for Alzheimer's disease (CERAD). part II. standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 41, 479–486. doi: 10.1212/wnl.41.4.479
- Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., et al. (2012). National institute on aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol.* 123, 1–11. doi: 10.1007/s00401-011-0910-3
- Morawski, M., Schilling, S., Kreuzberger, M., Waniek, A., Jager, C., Koch, B., et al. (2014). Glutaminy cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer's disease. *J. Alzheimers Dis.* 39, 385–400. doi: 10.3233/JAD-131535
- Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., et al. (2002). Intraneuronal Abeta42 accumulation in Down syndrome brain. *Amyloid* 9, 88–102. doi: 10.3109/13506120208995241
- Murdoch, J. C., Rodger, J. C., Rao, S. S., Fletcher, C. D., and Dunnigan, M. G. (1977). Down's syndrome: an atheroma-free model. *Br. Med. J.* 2, 226–228.
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., et al. (2015). Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. *Brain* 138, 1370–1381. doi: 10.1093/brain/awv050
- Neale, N., Padilla, C., Fonseca, L. M., Holland, T., and Zaman, S. (2018). Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. *Neuroimage Clin.* 17, 263–271. doi: 10.1016/j.nicl.2017.10.022
- Olichney, J. M., Hansen, L. A., Hofstetter, C. R., Grundman, M., Katzman, R., Thal, L. J., et al. (1995). Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. *Arch. Neurol.* 52, 702–708. doi: 10.1001/archneur.1995.00540310076019
- Oyama, F., Cairns, N. J., Shimada, H., Oyama, R., Titani, K., Ihara, Y., et al. (1994). Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. *J. Neurochem.* 62, 1062–1066. doi: 10.1046/j.1471-4159.1994.62031062.x
- Palmqvist, S., Scholl, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., et al. (2017). Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nat. Commun.* 8:1214. doi: 10.1038/s41467-017-01150-x
- Perez, S. E., Miguel, J. C., He, B., Malek-Ahmadi, M., Abrahamson, E. E., Ikonomic, M. D., et al. (2019). Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia. *Acta Neuropathol.* 137, 413–436. doi: 10.1007/s00401-019-01965-6
- Petersen, M. E., Rafii, M. S., Zhang, F., Hall, J., Julovich, D., Ances, B. M., et al. (2021). plasma total-tau and neurofilament light chain as diagnostic biomarkers of Alzheimer's disease dementia and mild cognitive impairment in adults with Down syndrome. *J. Alzheimers Dis.* 79, 671–681. doi: 10.3233/JAD-201167
- Petersen, M. E., Zhang, F., Schupf, N., Krinsky-McHale, S. J., Hall, J., Mapstone, M., et al. (2020). Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: an Alzheimer's biomarker consortium-Down syndrome (ABC-DS) study. *Alzheimers Dement. (Amst)* 12:e12039. doi: 10.1002/dad2.12039
- Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., and Launer, L. J. (2002). Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. *Neurology* 58, 1629–1634. doi: 10.1212/wnl.58.11.1629
- Pivtoraiko, V. N., Abrahamson, E. E., Leurgans, S. E., DeKosky, S. T., Mufson, E. J., Ikonomic, M. D., et al. (2015). Cortical pyroglutamate amyloid-beta levels and cognitive decline in Alzheimer's disease. *Neurobiol. Aging* 36, 12–19. doi: 10.1016/j.neurobiolaging.2014.06.021
- Planton, M., Saint-Aubert, L., Raposo, N., Payoux, P., Salabert, A. S., Albuquer, J. F., et al. (2020). Florbetapir regional distribution in cerebral amyloid angiopathy and Alzheimer's disease: a PET study. *J. Alzheimers Dis.* 73, 1607–1614. doi: 10.3233/JAD-190625
- Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., et al. (2013). White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease. *JAMA Neurol.* 70, 455–461. doi: 10.1001/jamaneurol.2013.1321
- Pucci, F., Machado, G., Solera, E., Cenovic, F., Arruda, C., Braga, C., et al. (2016). Blood pressure levels and body mass index in Brazilian adults with Down syndrome. *Sao Paulo Med. J.* 134, 330–334. doi: 10.1590/1516-3180.2016.0057180316
- Rafii, M. S., Ances, B. M., Schupf, N., Krinsky-McHale, S. J., Mapstone, M., Silverman, W., et al. (2020). The AT(N) framework for Alzheimer's disease in adults with Down syndrome. *Alzheimers Dement. (Amst)* 12:e12062. doi: 10.1002/dad2.12062

- Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., et al. (2017). APP/Abeta structural diversity and Alzheimer's disease pathogenesis. *Neurochem. Int.* 110, 1–13. doi: 10.1016/j.neuint.2017.08.007
- Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., et al. (1993). beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. *Proc. Natl. Acad. Sci. U S A* 90, 10836–10840. doi: 10.1073/pnas.90.22.10836
- Roher, A. E., Palmer, K. C., Yurewicz, E. C., Ball, M. J., and Greenberg, B. D. (1993). Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. *J. Neurochem.* 61, 1916–1926. doi: 10.1111/j.1471-4159.1993.tb09834.x
- Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., et al. (2007). Imaging beta-amyloid burden in aging and dementia. *Neurology* 68, 1718–1725. doi: 10.1212/01.wnl.0000261919.22630.ea
- Russo, C., Saido, T. C., DeBusk, L. M., Tabaton, M., Gambetti, P., Teller, J. K., et al. (1997). Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. *FEBS Lett.* 409, 411–416. doi: 10.1016/s0014-5793(97)00564-4
- Sabbagh, M. N., Fleisher, A., Chen, K., Rogers, J., Berk, C., Reiman, E., et al. (2011). Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. *Arch. Neurol.* 68, 1461–1466. doi: 10.1001/archneurol.2011.535
- Saido, T. C., Iwatsubo, T., Mann, D. M., Shimada, H., Ihara, Y., Kawashima, S., et al. (1995). Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. *Neuron* 14, 457–466. doi: 10.1016/0896-6273(95)90301-1
- Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., and Kawashima, S. (1996). Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. *Neurosci. Lett.* 215, 173–176. doi: 10.1016/0304-3940(96)12970-0
- Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G., et al. (2006). On the seeding and oligomerization of pGlu-amyloid peptides (*in vitro*). *Biochemistry* 45, 12393–12399. doi: 10.1021/bi0612667
- Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., et al. (2008). Glutaminyl cyclase inhibition attenuates pyroglutamate A β and Alzheimer's disease-like pathology. *Nat. Med.* 14, 1106–1111. doi: 10.1038/nm.1872
- Schlenzig, D., Manhart, S., Cinar, Y., Kleinschmidt, M., Hause, G., Willbold, D., et al. (2009). Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. *Biochemistry* 48, 7072–7078. doi: 10.1021/bi900818a
- Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., et al. (2017). Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. *Neuroimage Clin.* 13, 130–137. doi: 10.1016/j.nicl.2016.11.008
- Sullivan, C. P., Berg, E. A., Elliott-Bryant, R., Fishman, J. B., McKee, A. C., Morin, P. J., et al. (2011). Pyroglutamate-A β 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-A β 11 forming the central core. *Neurosci. Lett.* 505, 109–112. doi: 10.1016/j.neulet.2011.09.071
- Teller, J. K., Russo, C., DeBusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., et al. (1996). Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. *Nat. Med.* 2, 93–95. doi: 10.1038/nm0196-93
- Tudorascu, D. L., Anderson, S. J., Minhas, D. S., Yu, Z., Comer, D., Lao, P., et al. (2019). Comparison of longitudinal A β in nondemented elderly and Down syndrome. *Neurobiol. Aging* 73, 171–176. doi: 10.1016/j.neurobiolaging.2018.09.030
- Tudorascu, D. L., Laymon, C. M., Zammit, M., Minhas, D. S., Anderson, S. J., Ellison, P. A., et al. (2020). Relationship of amyloid beta and neurofibrillary tau deposition in neurodegeneration in aging Down syndrome (NiAD) study at baseline. *Alzheimers Dement. (N Y)* 6:e12096. doi: 10.1002/trc2.12096
- Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A., van Berckel, B. N. M., et al. (2021). Molecular imaging approaches in dementia. *Radiology* 298, 517–530. doi: 10.1148/radiol.2020200028
- Vinters, H. V. (1987). Cerebral amyloid angiopathy. A critical review. *Stroke* 18, 311–324. doi: 10.1161/01.str.18.2.311
- Viswanathan, A., and Greenberg, S. M. (2011). Cerebral amyloid angiopathy in the elderly. *Ann. Neurol.* 70, 871–880. doi: 10.1002/ana.22516
- Wilcock, D. M., Schmitt, F. A., and Head, E. (2016). Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome. *Biochim. Biophys. Acta.* 1862, 909–914. doi: 10.1016/j.bbdis.2015.11.007
- Wilson, L. R., Vatansever, D., Annus, T., Williams, G. B., Hong, Y. T., Fryer, T. D., et al. (2019). Differential effects of Down's syndrome and Alzheimer's neuropathology on default mode connectivity. *Hum. Brain Mapp.* 40, 4551–4563. doi: 10.1002/hbm.24720
- Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985). Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. *Ann. Neurol.* 17, 278–282. doi: 10.1002/ana.410170310
- Yamada, M. (2015). Cerebral amyloid angiopathy: emerging concepts. *J. Stroke* 17, 17–30. doi: 10.5853/jos.2015.17.1.17
- Yamin, G., and Teplow, D. B. (2017). Pittsburgh compound-B (PiB) binds amyloid beta-protein protofibrils. *J. Neurochem.* 140, 210–215. doi: 10.1111/jnc.13887
- Zammit, M. D., Laymon, C. M., Betthausen, T. J., Cody, K. A., Tudorascu, D. L., Minhas, D. S., et al. (2020). Amyloid accumulation in Down syndrome measured with amyloid load. *Alzheimers Dement. (Amst)* 12:e12020. doi: 10.1002/dad2.12020
- Zammit, M. D., Tudorascu, D. L., Laymon, C. M., Hartley, S. L., Zaman, S. H., Ances, B. M., et al. (2021). PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. *Neuroimage* 228:117728. doi: 10.1016/j.neuroimage.2021.117728
- Zigman, W. B., Devenny, D. A., Krinsky-McHale, S. J., Jenkins, E. C., Urv, T. K., Wegiel, J., et al. (2008). Alzheimer's disease in adults with Down syndrome. *Int. Rev. Res. Ment. Retard.* 36, 103–145. doi: 10.1016/S0074-7750(08)00004-9
- Zigman, W. B., Schupf, N., Urv, T., Zigman, A., and Silverman, W. (2002). Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. *Am. J. Ment. Retard.* 107, 161–174. doi: 10.1352/0895-8017(2002)107<0161:IATPOA>2.0.CO;2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Pivtoraiko, Racic, Abrahamson, Villemagne, Handen, Lott, Head and Ikonovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.